Answer
No; Rozlytrek (entrectinib) monotherapy is indicated for adults with advanced ROS1-positive non-small-cell lung cancer who have not previously been treated with ROS1 inhibitors.
Sources for this answer
- Rozlytrek 100 mg & 200 mg hard capsulesRoche Products Limited · emc · SmPC §4.1 Therapeutic Indications · Version 16Document updated
Sources checked